Prior studies have reported an association between greater eosinophil levels and improved survival outcomes in anti-CTLA-4-treated melanoma patients compared to those receiving chemotherapy, suggesting a potential role for baseline eosinophil count as a predictive biomarker (Ferrucci et al., 2017). This evidence concerns the gene CTLA4 and melanoma.